Grant is a Partner at Social Capital where he focuses on both early and late stage healthcare and life sciences investing.
Prior to joining Social Capital, Grant was a Vice President at J.P. Morgan where he helped lead the firm’s equity research coverage of the managed care and healthcare services industries. Previously, Grant worked in equity research at Goldman Sachs and Credit Suisse where he covered pharmaceutical and biotechnology companies.
During his time on the sell-side, Grant covered 60+ public companies and was directly involved in dozens of offerings and IPOs, including Signify Health,Oak Street Health, Progyny, and Intellia Therapeutics, among others. Through close work with both his covered public companies and their private competitors, Grant has developed deep expertise in some of the leading trends and technologies in healthcare today, including gene editing, tech-enabled primary care, biosimilar development, and more. He’s also been able to cultivate a large network of corporate, buy-side, and sell-side relationships across the sector that range from medtech to therapeutics to services.
Grant graduated with a B.B.A. in Finance from Ohio University where he spent all four of his undergraduate years co-managing a portion of the university’s Endowment Fund investing in public equities.
